NEW YORK (GenomeWeb News) –Amoy Diagnostics today said that China's State Food and Drug Administration has approved the company's EML4-ALK Fusion Gene Detection Kit for marketing in that country.

The approval allows Amoy to market the kit, which received CE Marking in January, for clinical use.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.